Get these analyses to your inbox — https://axialobservations.substack.com/ This is a newsletter for rough-around-the-edges ideas. More well thought out work can be found at — https://axial.substack.com/
Axial invests and partners in early-stage life sciences companies. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company — info@axialsprawl.com
New medicines #6 — June 13, 2020 — June 19, 2020
A weekly overview of the development of new medicines.
- AbbVie reported phase 3 data on Rinvoq (upadacitinib), JAKi monotherapy for atopic dermatitis:
- Improvement in skin clearance and itch
- At 15/30 mg: 70%/80% achieved EASI 75 at Week 16 versus 16% on placebo (p<0.001)
- https://www.prnewswire.com/news-releases/rinvoq-upadacitinib-monotherapy-shows-improvement-in-skin-clearance-and-itch-in-first-phase-3-study-for-atopic-dermatitis-301079479.html
- Acasti Pharma announced that the FDA has confirmed that its second phase 3 trial of CaPre, for the treatment of severe hypertriglyceridemia, will need to be performed on the full Intent to Treat (ITT) population:
